# US 2022/0033475 A1 · Compositions and methods for modulating factor viii function

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033475 A1
- Document ID: US20220033475A1
- Status: Published application
- Kind: A1
- Application number: 17/279,961
- Filed: 2019-10-23
- Published: 2022-02-03
- Earliest claimed: 2018-10-23
- Assignees: The Children's Hospital of Philadelphia
- Applicants: The Children's Hospital of Philadelphia
- Inventors: Valder R. Arruda; Benjamin Samelson-Jones
- Web page: https://patentgrep.com/patent/US20220033475A1

## CPC

- C07K 14/755: Factors VIII {, e.g. factor VIII C (AHF), factor VIII Ag (VWF)}
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 7/08: Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock (artificial tears A61P27/04)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Factor VIII variants and methods of use thereof are disclosed.

## Claims

### Claim at position 1

1: A Factor VIII (FVIII) variant wherein the B-domain is replaced with an amino acid sequence having at least 90% identity with SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, or SEQ ID NO: 18.

### Claim at position 2 (depends on 1)

2: The FVIII variant of claim 1, wherein the B-domain is replaced with an amino acid sequence comprising SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, or SEQ ID NO: 18.

### Claim at position 3 (depends on 1)

3: The FVIII variant of claim 1, wherein the B-domain is replaced with an amino acid sequence comprising SEQ ID NO: 18.

### Claim at position 4 (depends on 1)

4: The FVIII variant of claim 1, wherein said B domain consists of amino acids 741-1648 of SEQ ID NO: 1.

### Claim at position 5 (depends on 1)

5: The FVIII variant of claim 1, further comprising a substitution mutation of the Lys at position 659, the Asp at position 560, the Gln at position 561, the Asp at position 712, and/or the Lys at position 713.

### Claim at position 6

6: A Factor VIII (FVIII) variant comprising a substitution mutation of the Lys at position 659, the Asp at position 560, the Gln at position 561, the Asp at position 712, and/or the Lys at position 713.

### Claim at position 7 (depends on 6)

7: The FVIII variant of claim 6, wherein the Lys at position 659 is substituted with another amino acid.

### Claim at position 8 (depends on 7)

8: The FVIII variant of claim 7, wherein the Lys at position 659 is not substituted with a Pro, Gly, Met, or Leu;
wherein the Lys at position 659 is substituted with Trp, Arg, Ala, His, Tyr, Asp, Thr, Ser, Val, Phe, Gln, or Cys;
wherein the Lys at position 659 is substituted with Ser, Gln, or Cys; or
wherein the Lys at position 659 is substituted with Gln or Cys.

### Claim at position 9

9-11. (canceled)

### Claim at position 10 (depends on 7)

12: The FVIII variant of claim 7, wherein the Asp at position 560 is substituted with Ala, Val, Ile, Leu, His, Arg, or Lys; or wherein the Asp at position 560 is substituted with Ile or His.

### Claim 13

(canceled)

### Claim at position 12 (depends on 7)

14: The FVIII variant of claim 7, wherein the Gln at position 561 is substituted with Asp or Glu; or wherein the Gln at position 561 is substituted with Asp.

### Claim 15

(canceled)

### Claim at position 14 (depends on 7)

16: The FVIII variant of claim 7, wherein the Asp at position 712 is substituted with Ala, Val, Ile, or Leu; or wherein the Asp at position 712 is substituted with Leu.

### Claim 17

(canceled)

### Claim at position 16 (depends on 7)

18: The FVIII variant of claim 7, wherein the Lys at position 713 is substituted with Arg, Met, Tyr, Asp, Cys, or Gly; or wherein the Lys at position 713 is substituted with Gly.

### Claim 19

(canceled)

### Claim at position 18 (depends on 1)

20: The FVIII variant of claim 1, wherein said FVIII comprises amino acids 1-740 and 1649-2332 of SEQ ID NO: 1.

### Claim at position 19 (depends on 1)

21: A composition comprising at least one FVIII variant of claim 1 and at least one pharmaceutically acceptable carrier.

### Claim at position 20 (depends on 1)

22: A method for treatment of a hemostasis related disorder in a patient in need thereof comprising administration of a therapeutically effective amount of the FVIII variant of claim 1 in a pharmaceutically acceptable carrier.

### Claim at position 21 (depends on 22)

23: The method of claim 22, wherein said hemostasis related disorder is hemophilia A.

### Claim at position 22 (depends on 1)

24: An isolated nucleic acid molecule encoding the FVIII variant of claim 1, optionally wherein said FVIII variant comprises a signal peptide.

### Claim 25

(canceled)

### Claim at position 24 (depends on 24)

26: An expression vector comprising the nucleic acid molecule of claim 24 operably linked to a regulatory sequence, optionally wherein the vector is selected from the group consisting of an adenoviral vector, an adenovirus-associated vector, a retroviral vector, a plasmid, and a lentiviral vector.

### Claim 27

(canceled)

### Claim at position 26 (depends on 26)

28: A host cell comprising the vector of claim 26, optionally wherein said host cells are human cells.

### Claim 29

(canceled)

### Claim at position 28 (depends on 26)

30: A method for treatment of a hemostasis related disorder in a patient in need thereof comprising administration of a therapeutically effective amount of the vector of claim 26 in a pharmaceutically acceptable carrier.

### Claim at position 29 (depends on 1)

31: The activated form of the FVIII variant of claim 1.
